A Phase 1/2 Open-Label Multi-Center Trial to Assess Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of CLN-081 in Patients With Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Previously Received Platinum-Based Systemic Chemotherapy | NYU Langone Health

Go Back to All Clinical Trials

A Phase 1/2 Open-Label Multi-Center Trial to Assess Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of CLN-081 in Patients With Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Previously Received Platinum-Based Systemic Chemotherapy

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Non-small Cell Lung Cancer (nsclc)
Age: Between 18 Year(s) - 100 Year(s)
Gender: Male or Female

Other Inclusion Criteria:

1. Histologically or cytologically confirmed recurrent and/or metastatic Non-Small Cell Lung Cancer (NSCLC). 2. Documented EGFR exon 20 insertion mutation.

You may not be eligible for this study if the following are true:

1. For prior Exon 20 patients only: No Prior treatment with an EGFR exon 20 insertion-targeting drug (e.g., poziotinib, TAK788, tarloxotinib, JNJ- 61186372). 2. For all patients: Have any unresolved toxicity of Grade =2 from previous anti-cancer treatment, except for alopecia and skin pigmentation.